IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2011 by Shandong University.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
Shandong University
Information provided by:
Shandong University
ClinicalTrials.gov Identifier:
NCT01413035
First received: August 5, 2011
Last updated: August 8, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) derived from human umbilical cord/placenta at a dose of 1.0E+6 MSC/kg for type 2 diabetes.
| Condition | Intervention | Phase |
|---|---|---|
| Type 2 Diabetes | Biological: MSC | Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Safety/Efficacy Assessed Study on Transplantation Therapy Using Human Umbilical Cord/Placenta-derived Mesenchymal Stem Cells for Type 2 Diabetes Mellitus |
Further study details as provided by Shandong University:
Primary Outcome Measures:
- To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus [ Time Frame: 1 year ]
To assess efficacy of MSC through comparing the change of ITT, Hemoglobin A1c, FBG, PBG, C-peptide levels and T cell subsets with that of baseline.
- The change of insulin resistance index(ITT) compared with baseline.
- Rate of reducing exogenous insulin requirement compared with baseline.
- The change of Fast blood glucose (FBG) and Postmeal blood glucose (PBG) compared with baseline.
- A reduction of ≥1% in HbA1c compared with baseline.
- The change of C-peptide levels compared with baseline.
- The change of T cell subsets compared with baseline.
Secondary Outcome Measures:
- To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus [ Time Frame: 1 year ]To evaluate if there have occured the adverse everts such as fever, allergy, et al. and their severity.
| Estimated Enrollment: | 30 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | July 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: MSC and the oral hypoglycemic drugs
1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
|
Biological: MSC
1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
|
|
Experimental: MSC and insulins
1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
|
Biological: MSC
1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
|
|
Experimental: MSC and the combination of drugs and insulins
1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
|
Biological: MSC
1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
|
Detailed Description:
1. Intervention Details: Biological: umbilical cord/placenta-derived mesenchymal stem cells; Drug: 1. Oral Hypoglycemic Drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. 2. Insulins.
- 1st transplantation: after finishing all required examines according to protocol in Day 0, umbilical cord/placenta-derived MSCs are transplanted intravenously.
- 2nd transplantation: after finishing all required examines in Day 90, umbilical cord/placenta-derived-MSCs are transplanted intravenously if the effects of MSC are better than that before.
- At the same time, patients continue taking the oral hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and insulins which the patients have taken for controlling the higher blood sugar from Day 0 for 1 year. But the dose of the oral hypoglycemic drugs and insulins should be regulated according to the level of blood sugar.
2. Detailed Description:
- To evaluate the feasibility and safety of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus undergoing the oral hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and insulins.
- To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus undergoing the oral hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and insulins.
- This study will last 2 to 3 years. Participants will be randomly assigned to receive either MSC transplant and the oral hypoglycemic drugs or MSC transplant and insulins or MSC transplant and the combination of the oral hypoglycemic drugs and insulins (experimental group) or the oral hypoglycemic drugs or insulins or the combination of the oral hypoglycemic drugs and insulins (control group). Patients will undergo MSC transplant at the start of the study on Day 0 and take the oral hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and insulins for 1 year. As control, some patients take the oral hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and insulins for 1 year. At the same time, the dose of the oral hypoglycemic drugs and insulins should be regulated according to the level of blood sugar. After 3 months, patients will receive the second MSC transplantation. After six and twelve months from the first transplantation, patients will be evaluated.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Free will taking part in the study and ability to provide written informed consent
- Type 2 diabetes mellitus (as guideline WHO, 1999)
- Age 18-80 years old, Male/Female
- 19≤Body mass index (BMI)≤30㎏/㎡
- Fast blood glucose (FBG)≥7.0 mmol/L, and HbAc1≥7％
- Intravenous insulin tolerance test（ITT）indicate patient being insulin resistance
- Not pregnant or nursing
- No moderate or sever organ dysfunction: Ejection fraction>45%; Creatinine <176 mmol/L
- No active severe viral or fungus infection
Exclusion Criteria:
- Severe concurrent medical condition (e.g., serious heart disease, lung disease, or hematopoietic dysfunction, or liver dysfunction, or kidney dysfunction)
- Active infection requiring treatment
- Unexplained febrile illness
- Known immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection
- Psychiatric condition that would limit informed consent
- Patient has enrolled another clinical trial study within last 4 weeks.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01413035
Please refer to this study by its ClinicalTrials.gov identifier: NCT01413035
Contacts
| Contact: chengyun zheng, Ph. D | +86-531-85875635 | chengyun.zheng@ki.se, kdx2002@126.com |
Locations
| China, Shandong | |
| Department of Hematology of the 2nd Hospital of Shandong University | Recruiting |
| Jinan, Shandong, China, 250033 | |
| Contact: chengyun zheng, Ph. D +86-531-85875635 chengyun.zheng@ki.se, kdx2002@126.com | |
Sponsors and Collaborators
Shandong University
Investigators
| Principal Investigator: | chengyun zheng, Ph. D | Department of Hematology of The 2nd Hospital of Shandong University |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Chengyun Zheng, Department of Hematology of the 2nd Hospital of Shandong University |
| ClinicalTrials.gov Identifier: | NCT01413035 History of Changes |
| Other Study ID Numbers: |
diabetes |
| Study First Received: | August 5, 2011 |
| Last Updated: | August 8, 2011 |
Keywords provided by Shandong University:
|
Diabetes Diabetes Medicines: Oral Hypoglycemic Drugs and Insulins. Umbilical Cord/placenta-Derived MSC Transplantation |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Insulin, Globin Zinc Insulin Hypoglycemic Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 23, 2017